Literature DB >> 6157298

Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid.

L Svanberg, B Astedt, I M Nilsson.   

Abstract

Abruptio placentae is known to have a bad prognosis for the fetus. Pathologic proteolysis, e.g. a pathologic activation of the coagulation mechanism and/or the fibrinolytic system is known to be a common complication in such cases. Analysis of the coagulation factors and components of the fibronlytic system in the acute stage of 14 cases confirmed the earlier finding of mainly an activation of the fibrinolytic system, which argues for the use of a specific inhibitor. 73 consecutive cases of abruptio placentae were treated with tranexamic acid in the acute stage. 67 of the patients were immediately delivered by cesarean section. The remaining six patients were in early gestational age and were treated for a prolonged period. The perinatal mortality of the entire group was only 8 per cent and the maternal mortality nil. None of the cases were complicated by hemorrhagic diathesis or thromboses. We believe that routine immediate treatment with tranexamic acid can reduce the perinatal mortality in cases of abruptio placentae.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157298     DOI: 10.3109/00016348009154628

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

Review 1.  Clinical application of inhibitors of fibrinolysis.

Authors:  M Verstraete
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

Review 2.  Tranexamic acid: a review of its use in surgery and other indications.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Role of Intravenous Tranexamic Acid on Caesarean Blood Loss: A Prospective Randomised Study.

Authors:  Irene Ray; Ratneshwar Bhattacharya; Somajita Chakraborty; Chiranjib Bagchi; Sima Mukhopadhyay
Journal:  J Obstet Gynaecol India       Date:  2016-06-25

4.  TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.

Authors:  Anne-Sophie Ducloy-Bouthors; Emmanuelle Jeanpierre; Imen Saidi; Anne-Sophie Baptiste; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen; Benjamin Hennart
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

5.  Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Sophie Bouthors; Benjamin Hennart; Emmanuelle Jeanpierre; Anne-Sophie Baptiste; Imen Saidi; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.